Active, Not Recruiting
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
NCT03236428
- Conditions
- Blood Protein Disorders, Hematologic Diseases, Hemic and Lymphatic Diseases, +8 more
- Locations
-
- Pacific Cancer Care Monterey, California, United States
- Colorado Blood Cancer Institute Denver, Colorado, United States
- Massachusetts General Hospital Boston, Massachusetts, United States
- Beth Israel Deaconess Medical Center Boston, Massachusetts, United States